Study study type PathologyT1T0Patientssample sizesROB Results

KRAS gene alteration defined cancer KRAS gene alteration defined cancer

versus no control (uncontrolled study)
sotorasib
CodeBreaK 100, 2021
  NCT03600883
DESCKRAS gene alteration defined cancer, metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)otorasib, administered orally at a dose of 960 mg once dailypatients with KRAS p.G12C-mutated advanced NSCLC previously treated with standard therapies124NA
no results
    no results